Type I receptor tyrosine kinases as targets for therapy in breast cancer

Journal of Mammary Gland Biology and Neoplasia

Volumn 2, Issue 2, 1997, Pages 165-174

  Baselga, José ^a   Mendelsohn, John ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Breast cancer; Epidermal growth factor receptor; ErbB2; HER2 neu; Monoclonal antibodies; Tyrosine kinase inhibitors; Tyrosine kinase receptors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE;

ANIMAL; BREAST TUMOR; DRUG ANTAGONISM; FEMALE; HUMAN; MOUSE; NUDE MOUSE; REVIEW; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; FEMALE; HUMANS; MICE; MICE, NUDE; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TRANSPLANTATION, HETEROLOGOUS;

EID: 0031107242     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026355831693     Document Type: Article

References (57)

1. D. Barnes and G. Sato (1980). Serum-free cell culture: a unifying approach. Cell 22:649-655.
2. S. A. Haronson (1991). Growth Factors and Cancer. Science 254:1146-1153.
3. E. Di Marco, J. H. Pierce, T. P. Fleming, et al., (1989). Autocrine interaction between TGF alpha and the EGF-receptor:quantitative requirements for induction of the malignant phenotype. Oncogene 4:831-838.
4. HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc. Natl. Acad. Sci. U.S.A. 84:7159-7163.
5. P. P. Di Fiore, J. H. Pierce, M. H. Kraus, D. Segatto, C. R. King, and S. A. Aaronson (1987). erbR-2 is a potent oncogene when overexpressed in NIH-3T3 cells. Science 237:178-182.
6. M. B. Sporn and G. J. Todaro (1985). Autocrine growth factors and cancer. Nature 313:747-751.
7. T. Kawamoto, J. D. Sato, A. Le, J. Polikoff, G. H. Sato, and J. Mendelsohn (1983). Growth stimulation of A431 cells by EGF: Identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc. Natl. Acad. Sci. U.S.A. 80:1337-1341.
8. G. N. Gill, T. Kawamoto, C. Cochet, et al., (1984). Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J. Biol. Chem. 259:7755-7760.
9. J. D. Sato, T. Kawamoto, A. D. Le, J. Mendelsohn, J. Polikoff, and G. H. Sato (1983). Biological effect in vitro of monoclonal antibodies to human EGF receptors. Mol. Biol. Med. 1:511-529.
10. H. Sunada, B. Magun, J. Mendelsohn, and C. L. MacLeod (1986). Monoclonal antibody against EGF receptor is internalized without stimulating receptor phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 83:3825-3829.
11. H. Sunada, P. Yu, J. S. Peacock, and J. Mendelsohn (1990). Modulation of tyrosine serine and threonine phosphorylation and intracellular processing of the epidermal growth factor receptor by anti-receptor monoclonal antibody. J. Cell Physiol. 142:284-292.
12. T. Kawamoto, J. Mendelsohn, A. Le, G. H. Sato, C. S. Lazar, and G. N. Gill (1984). Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells. J. Biol. Chem. 259:7761-7766.
13. C. L. Arteaga, E. Coronado, and C. K. Osborne (1988). Blockade of the epidermal growth factor receptor inhibits transforming growth factor alpha induced but not estrogen-induced growth of hormone-dependent human breast cancer. Mol. Endocrinol. 2:1064-1069.
14. S. E. Bates, N. E. Davidson, E. M. Valverius, et al., (1988). Expression of transforming growth factor-a and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol. Endocrinol. 2:543-555.
15. S. E. Bates, E. M. Valverius, B. W. Ennis, et al., (1990). Expression of TGF-α/EGF receptor pathway in normal human breast epithelial cells. Endocrinol 126:597-607.
16. B. W. Ennis, E. M. Valverius, M. E. Lippman, et al., (1989). Monoclonal anti-EGF receptor antibodies inhibit the growth of malignant and nonmalignant human mammary epithelial cells. Mol. Endocrinol. 3:1830-1838.
17. H. Masui, T. Kawamoto, J. D. Sato, B. Wolf, G. H. Sato, and J. Mendelsohn (1984), Inhibition of human tumor cells in atymic mice by anti-EGF receptor monoclonal antibodies. Cancer Res. 44:1002-1007.
18. J. Mendelsohn (1989). Potential clinical applications of anti-EGF receptor monoclonal antibodies. In M. Furth and M. Greaves, (eds.), Cancer Cells. Cold Spring Harbor Press, New York, pp. 359-362.
19. Z. Fan, H. Masui, I. Altas, and J. Mendelsohn (1993). Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 53: 4322-4328.
20. H. Modjtahedi, J. M. Styles, and C. J. Dean (1993). The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468. Br. J. Cancer 67:247-253.
21. H. Modjtahedi, S. Eccles, G. Box, J. Styles, and C. Dean (1993). Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. Br. J. Cancer 67:254-261.
22. 111Indium labeled anti-EGF receptor monoclonal antibody. J. Natl. Cancer Inst. 81:1616-1625.
23. E. Aboud-Pirak, E. Hurwitz, M. E. Pirak, F. Bellot, J. Schlessinger, and M. Sela (1988). Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J. Natl. Cancer Inst. 80:1605-1611.
24. D. I. Marks and R. M. Fox (1991). DNA damage, poly(ADP-ribosyl)ation and apoptotic cell death as a potential common pathway for cytotoxic drug action. Biochem. Pharmacol. 42:1859-1867.
25. X. Wu, Z. Fan, H. Masui, N. Rosen, and J. Mendelsohn (1995). Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J. Clin. Invest. 95:1897-1905.
26. J. Baselga, L. Norton, H. Masui, et al., (1993). Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst. 85:1327-1333.
27. J. Baselga, L. Norton, K. Coplan, R. Shalaby, and J. Mendelsohn (1994). Antitumor activity of placitaxel in combination with anti-growth factor receptor monoclonal antibodies in breast cancer xenografts. Proc. Am. Assoc. Cancer Res. (Abstract) 35:2262.
28. C. Divgi, C. Welt, M. Kris, et al., (1991). Phase I and imaging trial of indium-111 labeled anti-EGF receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J. Natl. Cancer Inst. 83:97-104.
29. 111 In. Proc. Am. Assoc. Clin. Oncol. (Abstract) 12:368.
30. M. Bos, J. Mendelsohn, D. Bowden, et al., (1996). Phase I Studies of Anti-Epidermal Growth Factor Receptor (EGFR) Chimeric Monoclonal Antibody C225 in Patients with EGFR Overexpressing Tumors. Proc. Am. Soc. Clin. Oncol. (Abstract)
31. U. Rodeck, N. Williams, U. Murthy, and M. Herlyn (1990). Monoclonal antibody 425 inhibits growth stimulation of carcinoma cells by exogenous EGF and tumor-derived EGF/TGF-α. J. Cell. Biochem. 44:69-79.
32. S. Dadparvar, L. Krishna, C. Miyamoto, et al., (1994). Indium-111-labeled anti-EGFr-425 scintigraphy in the detection of malignant gliomas. Cancer 73:884-889.
33. R. Perez-Soler, N. J. Donato, D. M. Shin, et al., (1994). Tumor epidermal growth factor receptor studies in patients with nonsmall-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852. J. Clin. Oncol. 12:730-739. Published erratum appears in J. Clin. Oncol. 12(7):1526.
34. M. D. Waterfield, E. L. U. Mayes, P. Stroobant, et al. (1984). A monoclonal antibody to the human epidermal growth factor receptor. J. Cell. Biochem. 20:149-161.
35. H. P. Kalofonos, T. R. Pawlikoska, A. Hemingway, et al., (1989). Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J. Nucl. Med. 30:1636-1645.
36. J. A. Drebin, U. C. Link, D. F. Stern, R. A. Weinberg, and M. I. Greene (1985). Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41:695-706.
37. J. A. Drebin, V. C. Link, R. A. Weinberg, and M. I. Greene (1986). Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc. Natl. Acad. Sci. U.S.A. 83:9129-9133.
38. B. M. Fendly, M. Winget, R. M. Hudziak, M. T. Lipari, M. A. Napier, and A. Ullrich (1990). Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor to HEK2/neu gene product. Pepe. 50:1550-1558.
39. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9:1165-1172.
40. S. J. McKenzie, P. J. Marks, T. Lam, et al., (1989). Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene 4:543-548.
41. I. Stancovski, E. Hurwitz, D. Leitner, A. Ullrich, Y. Yarden, and M. Sela (1991). Mechanistic aspects of the opposing effects of monoclonal antibodies to the erbB-2 receptor on tumor growth. Proc. Natl. Acad. Sci. U.S.A. 88:8691-8695.
42. M. C. Hancock, B. C. Langton, T. Chan, et al., (1991). A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res. 51:4575-4580.
43. HER2 monoclonal antibodies. Cancer Immunology Immunotherapy 37:255-263.
44. R. J. Pietras, B. M. Fendly, V. R. Chazin, M. D. Pegram, S. D. Howell, and D. J. Slamon (1994). Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9:1829-1838.
45. T. Nishimura, Y. Nakamura, H. Tsukamoto, et al., (1992). Human c-erb B proto-oncogene product as a target for bispecific-antibody-directed adoptive tumor immunotherapy. Int'l. J. Cancer 50:800-804.
46. L. M. Weiner, M. Holmes, G. P. Adams, F. LaCreta, P. Watts, and I. Garcia de Palazzo (1993). A human tumor xenograft model of therapy with a bispecific monoclonal antinody targeting c-erb-B-2 and CD16. Cancer Res. 53:94-100.
47. F. H. Valone, P. A. Kaufman, P. A. Guyre, et al., (1995). Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J. Clin. Oncol. 13:2281-2292.
48. C. M. Weiner, D. Ring, W. Li, et al., (1994). Phase I trial of 2B1, a bispecific murine monoclonal antibody targeting c-erb-2 and CD16. Proc. Am. Soc. Clin. Oncol. (Abstract) 13:978.
49. P. Carter, L. Presta, C. M. Gorman, et al., (1992). Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 89:4285-4289.
50. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14:737-744.
51. M. C. Hancock, B. C. Langton, J. Chan, et al., (1991). A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res. 51:4575-4580.
52. c-erbB-2 Signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res. 54:3758-3765.
53. M. Pegram, A. Lipton, R. Pietras, et al. (1995). Phase II study of intravenous recombinant humanized anti-p185 HER-2 monoclonal antibody (rhuMAb HER-2) plus Cisplatin in patients with HER-2/neu overexpressing metastasic breast cancer. Proc. Am. Soc. Clin. Oncol. (Abstract) 1282: 7812-7711.
54. A. Levitzki and A. Gazit (1995). Tyrosine kinase inhibition: an approach to drug development. Science 267:1782-1787.
55. N. Osherov, A. Gazit, C. Gilon, A. Levitzki (1993). Selective inhibition of the epidermal growth factor and Her2/Neu receptors by tyrphostins. J. Biol. Chem. 268:11134-11142.
56. D. W. Fry, A. J. Kraker, A. McMichael, et al., (1994). A Specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265:1093-1095.
57. M. Bos, J. Mendelsohn, Y. M. Kim, D. W. Fry, and J. Baselga (1996). A tyrosine kinase inhibitor prevents ligand-induced receptor activation and inhibits growth of cancer cell lines expressing the epidermal growth factor receptor. Proc. Am. Assoc. Cancer Res. (Abstract) 232:768-771.